E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
This study aims to investigate gene expression following vaccination with 4CMenB and relate this to vaccine reactions and to immune response |
|
E.1.1.2 | Therapeutic area | Body processes [G] - Genetic Phenomena [G05] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To describe the kinetics of global gene expression (i.e. the pattern of which genes are switched on/off) in whole blood, following vaccination with 4CMenB vaccine in healthy infants. |
|
E.2.2 | Secondary objectives of the trial |
1. To compare gene expression following vaccination with 4CmenB to immunogenicity as determined by serum bactericidal antibody titres (a measure of how well the body has made antibodies capable of killing MenB)against reference strains of serogroup B N. meningitidis.
2. To investigate changes in the epigenome within individuals following vaccination with 4CMenB.
3. To relate changes in gene expression to changes in B cell populations.
4. To relate changes in gene expression to changes in plasma proteins.
5. To describe any changes in oro-pharyngeal Neiserrial flora occurring after vaccination,as determined by analysis of the pharyngeal microbiome.
Exploratory objectives
1. To explore relationships between reactogenicity, gene expression and immunogenicity (are gene expression patterns different between good / poor responders, are fever and immunogenicity related)
2. To explore genetic determinants of response to vaccination with 4CMenB
3. To explore the relati |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
•Healthy infants of two Caucasian parents (self-defined by parent) born between 37 and 42 weeks of gestation aged 8-12 weeks at time of first visit •Parent or legal guardian willing and able to comply with the requirements of the protocol and have internet access for the duration of the study. •Parent/legal guardian who have given informed consent for their child’s participation in the study
|
|
E.4 | Principal exclusion criteria |
•Non-Caucasian infants •Children of parents who are on the delegation log for this study •Parent/ legal guardian under the age of 18 •History of invasive meningococcal B disease •Previous vaccination with meningococcal serogroup B vaccine •History of being a household contact with a case of confirmed bacterial meningitis •Prior administration of any vaccine or planned administration of any vaccine not specified in the study protocol, with the exception of Hepatitis B vaccine and Influenza vaccines (which can be given 14 days before or after study vaccines), or BCG (which can be administered 28 days before or after study vaccines) •Prior or planned receipt of any other investigational vaccine or drug •Confirmed or suspected immunodeficiency •A family history of congenital or hereditary immunodeficiency, or maternal HIV •Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid). Nasal, topical or inhaled steroids are allowed. •History of allergy to any component of the vaccine •Major congenital defects or serious chronic illness •History of any neurologic disorders or seizures •Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period •Any other condition which, in the opinion of the investigator, may interfere with the ability to fulfil study requirements (this may include plans to move house and language comprehension). •No internet access for the duration of the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Analysis of differentially expressed genes in whole blood at 4hr, 24hr, 3d and 7d timepoints following vaccination with 4CMenB and routine immunisations, or routine immunisations alone. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Analysis of differentially expressed genes in whole blood at 4hr, 24hr, 3d and 7d time points following the 2nd and 3rd doses of 4CMenB vaccine when given at 2, 4 and 12 months of age together with routine immunisations, or following routine immunisations alone given at equivalent time points |
|
E.5.2 | Secondary end point(s) |
• To compare gene expression following vaccination with 4CMenB to immunogenicity as determined by serum bactericidal antibody titres against reference strains of serogroup B N. meningitidis • To investigate changes in the epigenome within individuals following vaccination with 4CMenB • To relate changes in gene expression to changes in B cell populations • To relate changes in gene expression to changes in plasma proteins • To describe any changes in the oro-pharyngeal flora occurring after vaccination, as determined by analysis of the overall oro- pharyngeal Neisseria microbiome
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• Measurement of SBA titre against three Neisseria meningitidis strains: NZ98/254, 5/99 and 44/76-SL (as well as additional strains as indicated) at 5, and 13 months of age in children receiving 4CMenB at 2, 4 and 12 months of age • Measurement of epigenome modifications, potentially including changes in methylation and histone modification DNA • Quantification of 4CMenB antigen-specific antibody secreting cells by ELISPOT at day 7 and day 28 after the 2nd and 3rd doses of 4CMenB vaccine given at 2, 4 and 12 months of age • Analysis of gene expression profiles in PBMCs +/- lymphocyte subsets • Exploratory measurement of plasma proteins. • Investigation of the oro-pharyngeal Neisseria microbiome, at 5 and 13 months in all study children. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Yes |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Usual paediatric immunisations according to the UK national immunisation schedule |
|
E.8.2.4 | Number of treatment arms in the trial | 8 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of study will be when all biological samples have been processed |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 5 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 8 |